Peptide Cycling Protocols: A Practical Guide

GH Secretagogues: The Receptor Desensitisation Question

GH secretagogues (CJC-1295, Ipamorelin, GHRP-2, GHRP-6, Sermorelin) work by stimulating GHRH receptors or ghrelin receptors on pituitary somatotrophs. Chronic, continuous stimulation of these receptors raises concern for desensitisation — receptor downregulation reducing response over time. This is particularly well-documented for GHRPs (GHRP-2, GHRP-6), which show receptor desensitisation with high-frequency dosing.

Common cycling approaches for GH secretagogues: 5 days on, 2 days off (the "5/2" protocol) — preserving weekend sensitivity reset while maintaining weekday stimulation; or 12 weeks on, 4 weeks off. CJC-1295 without DAC has a short enough half-life that its effects resolve between daily doses and receptor recovery is faster. CJC-1295 with DAC (week-long half-life) requires longer off periods (2–4 weeks after a 12-week cycle) due to persistent receptor occupancy. Ipamorelin has less pronounced desensitisation than GHRPs and tolerates 5-day-on/2-day-off or 6-on/1-off approaches.

BPC-157 and TB-500: Goal-Based Cycling

BPC-157 and TB-500 do not have well-documented receptor desensitisation concerns — their mechanisms (growth factor modulation, VEGFR2 signalling, cytoskeletal effects) do not involve simple receptor agonism in the same way. Cycling for these compounds is typically goal-based: use during acute injury or intensive training periods, then reduce or discontinue when the therapeutic goal is achieved or a maintenance plateau is reached.

Common approaches: 8–12 week cycles for active injury healing with 4–6 week breaks; maintenance dosing (2–3×/week instead of daily) during periods without active injury; or continuous low-dose use (250 mcg 3×/week) for chronic conditions. There is no strong evidence that continuous BPC-157 use causes harm, but cost and the possibility of diminishing returns on tissue repair once healing is complete are practical reasons to cycle off after a full healing course.

Nootropic Peptides: Tolerance Considerations

Selank and Semax have no documented pharmacological tolerance (unlike benzodiazepines, which downregulate GABA-A receptors with chronic use). Community experience with both is largely consistent: effects remain fairly stable with regular use rather than fading. However, many users report a subjective "freshness" to cognitive enhancement after periodic breaks — whether this reflects true pharmacological tolerance, psychological hedonic adaptation, or simply variation in baseline cognitive state is unclear.

Practical cycling approaches for nootropics: 5 days on / 2 days off (most common, matches work week); or continuous use with monthly 1-week breaks. Dihexa, given its structural mechanism, is often used in more defined 4–8 week courses with longer (4–8 week) breaks to allow any structural changes to consolidate before another cycle.

Epithalon and Longevity Peptides: Course-Based Protocols

Epithalon (and the broader bioregulator peptide category from Khavinson's work) is designed for defined courses rather than continuous use — mirroring the clinical study designs where benefits were demonstrated. The standard protocol: 5–10 mg daily for 10–20 consecutive days, run once or twice per year. This reflects both the research design and the hypothesis that telomerase activation produces durable effects between courses rather than requiring continuous exposure.

GHK-Cu for longevity use can be run more continuously (daily or 5×/week) without documented tolerance. SS-31 and Humanin are typically cycled in 8–12 week blocks with 4-week breaks, again based more on practical protocol management and cost than well-established biological requirements.

Weight Loss Peptides: Titration-Based Cycling

GLP-1 agonists (Semaglutide, Tirzepatide, Retatrutide) require a fundamentally different cycling approach: dose titration rather than on/off cycling. These compounds are titrated upward over weeks to minimize GI side effects (nausea, reduced appetite). Abrupt discontinuation can cause rebound hunger and weight regain as the GLP-1 receptor loses its exogenous stimulation.

Standard Semaglutide titration: start at 0.25 mg/week for 4 weeks, then 0.5 mg for 4 weeks, then 1.0 mg, up to 2.4 mg/week. Tirzepatide follows a similar ramp from 2.5 mg to 15 mg/week. If discontinuing, taper down over 4-6 weeks rather than stopping abruptly. Some researchers run indefinite maintenance at a lower dose rather than cycling off entirely.

AOD-9604 (the GH fragment for fat loss) does not require the same titration approach — it can be run in standard 8-12 week cycles with 4-week breaks, similar to GH secretagogues but without receptor desensitisation concerns since it does not stimulate GH release.

5-Amino-1MQ (a fat-loss peptide targeting NNMT enzyme) is typically run in 4-8 week cycles with breaks of equal length. As an enzyme inhibitor, it does not cause receptor desensitisation, but cycling allows NNMT activity to normalize between courses.

Immune and Antimicrobial Peptides: Course-Based Use

Thymosin Alpha-1, Thymalin, and LL-37 are typically used in defined courses rather than continuous administration. Thymosin Alpha-1 follows a clinical protocol of 1.6 mg subcutaneously twice weekly for defined treatment periods (often 4-12 weeks), with reassessment between courses.

LL-37, the human antimicrobial peptide, is generally used for acute situations — active infections, wound healing support, or biofilm disruption. Typical courses run 2-4 weeks. Continuous long-term use is not well-studied and is not recommended given the peptide's potent immune-activating properties.

KPV (the anti-inflammatory tripeptide) can be used more continuously for chronic inflammatory conditions, but most protocols use 4-8 week cycles with 2-4 week breaks. Its mechanism (alpha-MSH fragment activity) does not show documented tolerance.

Sexual Health and Tanning Peptides: Acute Dosing

PT-141 (Bremelanotide) is unique among peptides in that it's typically used on-demand rather than in continuous cycles. The standard protocol is 1-2 mg administered 2-4 hours before desired effect. Using PT-141 daily rapidly causes tachyphylaxis (acute tolerance), so most protocols limit use to 2-3 times per week maximum with at least 48 hours between doses.

Melanotan II is run in loading and maintenance phases: 0.25-0.5 mg daily for 2-3 weeks (loading), then 0.5 mg once or twice weekly (maintenance). Some researchers cycle off entirely during winter months and reload before sun exposure seasons. Kisspeptin protocols vary by application — pulse dosing for hormonal support mirrors its natural pulsatile secretion.

How to Design Your Own Cycling Protocol

When no established protocol exists for a specific peptide, use these principles to design a rational cycling approach:

Step 1 — Identify the mechanism: Is it a receptor agonist (risk of desensitisation)? An enzyme modifier? A signaling molecule? Receptor agonists generally need cycling; enzyme targets and structural peptides often don't.

Step 2 — Consider the half-life: Peptides with longer half-lives need longer washout periods. Short half-life compounds clear quickly and can use shorter off-periods. As a rule: off-period should be at minimum 5 half-lives to ensure near-complete clearance.

Step 3 — Define the goal: Acute goals (injury healing, infection treatment) dictate use-until-resolved protocols. Chronic goals (body composition, cognitive enhancement, longevity) require sustainable cycling schedules you can maintain long-term.

Step 4 — Start conservative: When in doubt, use a 3:1 ratio (e.g., 12 weeks on, 4 weeks off) and monitor whether effects diminish over the cycle. If effects remain strong through the full on-period, the cycle length is appropriate.

Use our peptide calculator for exact dosing math within your cycle, and our individual peptide guides for compound-specific protocol details.

Common Cycling Mistakes

Mistake 1 — Cycling everything the same way. A 12-on/4-off schedule works for GH secretagogues but is wrong for Epithalon (course-based), PT-141 (on-demand), and Semaglutide (titration). Match the cycling approach to the mechanism.

Mistake 2 — Cutting cycles short. Many peptide effects are cumulative and take 4-8 weeks to fully manifest. Stopping a BPC-157 healing cycle at week 3 because "nothing is happening" misses the window where most researchers report significant changes.

Mistake 3 — No washout between compounds. When switching from one peptide to another targeting the same receptor, allow a full washout period (minimum 5 half-lives) before starting the new compound. Overlapping similar mechanisms can cause compounded desensitisation.

Mistake 4 — Ignoring storage degradation. Reconstituted peptides degrade over time. If your 12-week cycle uses a vial reconstituted on day 1, the compound may be significantly degraded by week 8. Reconstitute only what you'll use in 4-6 weeks. See our peptide storage guide for details.

Mistake 5 — Stacking without staggering. Starting three new peptides simultaneously makes it impossible to identify which is responsible for effects (or side effects). Introduce one compound per cycle when building a stack.

Peptide Cycling Recommendations

Frequently Asked Questions